Abstract

 ABSTRACT
 Alzheimer’s disease is a top-10 deadly neurodegenerative disease based on WHO in 2019. Its characterized by a reduction in Choline Acetyltransferase (ChAt) of a substance that acts in the production of asetikolin. One of the ingredients of nature known to play a part in the increased memory of pegagan. To learn about the line of active compound mechanisms used in the treatment of alzheimer's, the study uses an in silico approach by analyzing target proteins and the compound's active compound on a network of compounds. This study used 12 test compounds and the ChAt receptor molecules. Networking design the interactions of these compounds using the sea target and STRING databases. The results of that interactions are visualized on the cytoscape device. Furthermore, the results also suggested thateight of compounds’stest that have interactions with ChAt receptors whereas the target proteins directly linked to ChAt receptors namely Tryptophan 5-hydroxylase 1 (PDB ID: 5tpg) and Zinc finger protein GLI (PDB ID: 4kmd). Thus, the pegagan active compound that acts most closely on protein target is Asiatic Acid, Brahmic Acid, -Humulene, -Caryophyllene, Bicyclogermacrene, Germacrene B, -Pinene, Caryophyllene.
 Keywords: Alzheimer's disease, Choline Acetyltransferase (ChAt), pegagan, in silico, network interaction
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
